Contrary to the myth of the lone entrepreneur, the U.S. government has been the most critical and successful early-stage investor in history. It provided life-saving grants to companies like SpaceX and Tesla and funded foundational technologies like mRNA, yet rarely receives credit for its pivotal role as a venture capitalist.

To de-risk their pipelines amidst capacity constraints and geopolitical uncertainty, some drug sponsors are paying for manufacturing slots months or even years ahead of time. This proactive strategy ensures that bioreactor time is secured, preventing potential development delays.

Government funders like the NIH are inherently risk-averse. The ideal model is for philanthropists to provide initial capital for high-risk, transformative studies. Once a concept is proven and "de-risked," government bodies can then fund the larger-scale, long-term research.

To fix market failures in drug development, sophisticated economic tools are used. Priority Vouchers let a firm fast-track an unrelated profitable drug, while Advanced Market Commitments (AMCs) are binding government promises to buy a future vaccine, guaranteeing a market where none exists.

Selling low-cost vaccines to organizations like Gavi isn't just charity for pharmaceutical companies. It creates massive economies of scale, lowering the cost of goods for their high-margin primary markets and increasing overall net profit, creating a powerful win-win incentive structure.

Both in the US (with Medicare/Medicaid) and China, the areas of medicine that see the most government spending on drugs also attract the most R&D investment. China strategically uses this mechanism to direct innovation towards its public health priorities.

Instead of ineffective grants to incumbents, the US should leverage its world-leading capital markets. By providing lightweight government backstops for private bank loans—absorbing partial default risk—it can de-risk private investment and unlock the massive capital needed for new factories without distorting market incentives.

For diseases affecting only the poorest populations, scientific success isn't enough. The key financial instrument is an "advanced purchase" guarantee from a government or large organization. This de-risks production for manufacturers, providing a viable business model where traditional profit motives fail.

Contrary to expectations, regulatory approvals were not the main challenge in scaling a COVID vaccine during the pandemic. The most significant constraint was the global supply chain for critical imported biomanufacturing components like filters and resins, as every country competed for the same limited resources.